Interleukin 6 (IL-6) is a multifunctional cytokine produced by a variety of lymphoid and non-lymphoid cells. It has been recently shown that IL-6 induces growth and differentiation in human B cells, promotes proliferation of certain hybridomas and plasmacytomas, inhibits the growth of fibroblasts and certain tumour cell lines, and induces the synthesis of certain 'acute phase' protein in liver cells (reviewed in Hirano et al., 1990) . Moreover, IL-6 has been also shown to act on lectinactivated T cell-proliferation (Helle, 1989) , on NK cells, and as a helper factor for the in vitro induction of cytotoxic T cells (Okada et al., 1988; Takai et al., 1988) . Thus, IL-6 participates in the regulation of immune responses, acute phase proteins (Ramadori et al., 1988) and may play a central role in host defence mechanisms (Hirano et al., 1990) .
In mice bearing transplantable solid tumours, increased levels of circulating IL-6 are detected and directly correlate with the extent of the tumour burden (McIntosh et al., 1989) . To the best of our knowledge only one study has investigated IL-6 in patients with cancer and reported increased circulating concentrations (Erroi et al., 1990) .
We have investigated the IL-6 serum concentrations and monocyte production in patients with advanced head and neck cancer (HNC) in different stages of disease, in comparison to healthy subjects. In this paper we first report that high amounts of IL-6 are detected in the sera of HNC patients, and that in HNC patients an increased IL-6 production by LPS activated monocytes takes place.
Monocytes were obtained from 19 male and three female patients with larynx (n = 10) and oral cavity (n = 6) and six oropharynx (n = 6) carcinoma and from 22 sex and age matched healthy subjects free from infections and drugs in the 2 weeks preceding blood sampling. Blood samples were withdrawn from fasting subjects between 8 and 9 am, 2-3 days before operation or radiotherapy.
Mononuclear cells were separated from peripheral citrated (1:9 v/v) blood, drawn in plastic syringes and anticoagulated with citrate (1:9 v/v). After centrifuging at 120g for 10min, at room temperature, platelet-rich plasma was discarded, cells were resuspended in phosphate buffered-saline (PBS) (pH 7.4) and centrifuged at 120 g for 10 min and platelets were removed. After dilution 1:2 with PBS, cells were layered into Ficoll-Hypaque (Lymphoprep, Immuno, Austria) and centrifuged at 400g for 20min at 22C. The cells at the interface were carefully removed with sterile plastic pipettes and washed by centrifuging at 400g for 20 min at 4°C with PBS. Monocytes were separated from mononuclear cells by adherence to plastic Petri dishes (Bevilacqua et al., 1981 Freshly isolated human peripheral blood monocytes from controls did not spontaneously release appreciable amounts of IL-6, whereas in seven out of 22 patients low concentrations (87.9 ± 32.5 pg 10-6 cells) of IL-6 were detected in supernatants of monocytes in the absence of LPS.
IL-6 production by LPS stimulated monocytes of HNC patients was significantly (P<0.0001) higher than those of controls (475.2 ± 86.4 and 55.4 ± 10.1 pg 106 cells, respectively), whereas no significant differences were observed in relation to cancer stage (I-II (n = 10) vs III-IV (n = 12) Stage: 485.9 ± 95.3 vs 466.3 ± 134.8 pg 10-6 cells) (Figure 1) .
Moreover, IL-6 levels detected in the sera of HNSC patients was significantly higher than those of controls (93.9 ± 7.06 vs 3.16 ± 1.9, respectively; P < 0.0001) ( Figure  2) . A significant linear (r = 0.75, P<0.0001) relationship has been found between IL-6 activated monocyte production and IL-6 serum levels in HNC patients and in control subjects.
Monocytes are the major source of IL-6 in whole blood (Kato et al., 1990) , so it is conceivable that the elevated levels in serum stem, at least in part from the increased spontaneous and LPS induced production by monocytes. In vitro, monocytes from HNC patients produce elevated IL-6 amounts not only after endotoxin stimulation, but in 30% of the patients there was a release of IL-6 in the absence of LPS stimulation. However, it has to be considered that the tumour-bearing state may prime cells, such as endothelial cells and fibroblasts, capable of producing IL-6 for enhanced release upon stimulation by other cytokines (Sanceau et al., 1990; Jabloson et al., 1989; McIntosh et al., 1989) Recently, the rapid appearance of IL-6 in the peripheral blood (Jabloson et al.. 1989) creased TNF production by penrpheral monocytes of patients affected by the same neoplastic disease (Gallo et al., 1991) .
Therefore, it is possible that increased IL-6 serum levels and monocyte production could be the expression of autocrine induction of this cytokine via TNF or could be directly related to tumour activation.
